<DOC>
	<DOC>NCT02175186</DOC>
	<brief_summary>The purpose of this study is to evaluate effectiveness of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention.</brief_summary>
	<brief_title>Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Peptic Ulcer</mesh_term>
	<criteria>Age between 20 and 80 years Patients undergoing percutaneous coronary intervention and need to take dual antiplatelet therapy continuously at least 12weeks Modified Lanza Score grade 01 measured by upper gastrointestinal endoscopy mild gastrointestinal symptom Creatinen in blood ≤ 3mg/dl BUN ≤ 50mg/dl Birilubin ≤ 3mg/dl AST and ALT ≤ 80U/L Pregnant or breast feeding History of Stomach or esophagus surgery Peptic ulcer or reflux esophagitis ZollingerEllison syndrome or primary esophageal motility disorders Malignant tumor Bleeding tendency or coagulopathy Contraindication of ALBIS Long term use of aspirin or P2Y12 receptor antagonist within 1month Patients who tool medicine such as PPI, APA,H2blocker, Muscarine receptor antagonist, antigastic agent, antacid, anticaogulant, Bisphosphonate agents, Cytotoxic drug, NSAID, adrenal cortex hormone agents (topical treatment is allowed) Terminal patient</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Gastritis</keyword>
	<keyword>Gastroduodenal Ulcer</keyword>
	<keyword>Percutaneous Coronary Revascularization</keyword>
	<keyword>Dual Antiplatelet Therapy</keyword>
</DOC>